Amphastar Pharmaceuticals AMPH Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amphastar Pharmaceuticals's operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amphastar Pharmaceuticals's operating lease right-of-use asset amortization?
- Amphastar Pharmaceuticals (AMPH) reported operating lease right-of-use asset amortization of $2.14M in Q1 2026.
- How has Amphastar Pharmaceuticals's operating lease right-of-use asset amortization changed year-over-year?
- Amphastar Pharmaceuticals's operating lease right-of-use asset amortization increased by 34.2% year-over-year, from $1.6M to $2.14M.
- What is the long-term trend for Amphastar Pharmaceuticals's operating lease right-of-use asset amortization?
- Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's operating lease right-of-use asset amortization has grown at a 18.8% compound annual growth rate (CAGR), from $3.27M to $6.51M.